Switchers, apply here, says HPRA
This article was originally published in OTC Bulletin
Irish medicines agency, the HPRA, has said it is “open” to prescription-to-OTC switch applications, especially if they are first-in-category switches, and will offer advice to firms that apply.
You may also be interested in...
Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview.
A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June.
In Part 2 of this exclusive interview, Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, tells HBW Insight what the association is doing to improve the prescription-to-OTC switch process in Germany.